MXPA03001287A - Uso de complejos metalicos conteniendo perfluoroalquilo como medios de contraste en imagenes rm para la representacion de placas, tumores y necrosis. - Google Patents

Uso de complejos metalicos conteniendo perfluoroalquilo como medios de contraste en imagenes rm para la representacion de placas, tumores y necrosis.

Info

Publication number
MXPA03001287A
MXPA03001287A MXPA03001287A MXPA03001287A MXPA03001287A MX PA03001287 A MXPA03001287 A MX PA03001287A MX PA03001287 A MXPA03001287 A MX PA03001287A MX PA03001287 A MXPA03001287 A MX PA03001287A MX PA03001287 A MXPA03001287 A MX PA03001287A
Authority
MX
Mexico
Prior art keywords
necroses
tumours
plaques
imaging
representation
Prior art date
Application number
MXPA03001287A
Other languages
English (en)
Spanish (es)
Inventor
Johannes Platzek
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10040380A external-priority patent/DE10040380B4/de
Application filed by Schering Ag filed Critical Schering Ag
Publication of MXPA03001287A publication Critical patent/MXPA03001287A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MXPA03001287A 2000-08-11 2001-07-23 Uso de complejos metalicos conteniendo perfluoroalquilo como medios de contraste en imagenes rm para la representacion de placas, tumores y necrosis. MXPA03001287A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10040380A DE10040380B4 (de) 2000-08-11 2000-08-11 Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Plaques
PCT/EP2001/008498 WO2002013874A2 (de) 2000-08-11 2001-07-23 Verwendung von perfluoralkylhaltigen metallkomplexen als kontrastmittel im mr-imaging zur darstellung von plaques, tumoren und nekrosen

Publications (1)

Publication Number Publication Date
MXPA03001287A true MXPA03001287A (es) 2003-10-06

Family

ID=7652860

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03001287A MXPA03001287A (es) 2000-08-11 2001-07-23 Uso de complejos metalicos conteniendo perfluoroalquilo como medios de contraste en imagenes rm para la representacion de placas, tumores y necrosis.

Country Status (26)

Country Link
EP (1) EP1307236A2 (sh)
JP (1) JP2004506025A (sh)
KR (1) KR20030022387A (sh)
CN (1) CN1469757A (sh)
AR (1) AR034139A1 (sh)
AU (2) AU2001277549B2 (sh)
BG (1) BG107542A (sh)
BR (1) BR0113188A (sh)
CA (1) CA2419223A1 (sh)
CZ (1) CZ2003392A3 (sh)
DE (1) DE10066210B4 (sh)
EE (1) EE200300061A (sh)
HR (1) HRP20030173A2 (sh)
HU (1) HUP0300736A3 (sh)
IL (1) IL154385A0 (sh)
MX (1) MXPA03001287A (sh)
NO (1) NO20030604L (sh)
NZ (1) NZ523932A (sh)
PL (1) PL365596A1 (sh)
RU (1) RU2290206C2 (sh)
SK (1) SK1572003A3 (sh)
TW (1) TWI296931B (sh)
UA (1) UA82642C2 (sh)
WO (1) WO2002013874A2 (sh)
YU (1) YU10603A (sh)
ZA (1) ZA200301949B (sh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10231799B4 (de) * 2002-07-10 2006-10-05 Schering Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Intravasalen Thromben
US7344704B2 (en) 2002-07-10 2008-03-18 Schering Ag Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of intravascular thrombi
DE102005008309A1 (de) * 2005-02-17 2006-08-24 Schering Ag Pharmazeutische Mittel enthaltend fluoralkylhaltige Metallkomplexe und Epothilone
DE102006021495A1 (de) * 2006-05-09 2007-11-15 Bayer Schering Pharma Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel zur Diagnose der Alzheimer Krankheit
US7887835B2 (en) * 2006-09-19 2011-02-15 Fujifilm Corporation Compound comprising a fluorine-substituted alkyl group and a liposome contrast medium comprising the compound
DE102006049821A1 (de) * 2006-10-18 2008-04-24 Bayer Schering Pharma Aktiengesellschaft Metallchelate mit perfluoriertem PEG-Rest, Verfahren zu deren Herstellung, sowie deren Verwendung
DE102007015598A1 (de) * 2007-03-29 2008-10-02 Heinrich-Heine-Universität Düsseldorf Verwendung von fluorhaltigen Verbindungen zu Diagnosezwecken mit Hilfe bildgebender Verfahren
JP2011190183A (ja) * 2010-03-11 2011-09-29 Noguchi Institute フルオラス化糖結合型クラウンエーテル誘導体
US9976072B2 (en) 2014-03-26 2018-05-22 Chevron U.S.A. Inc. Multicarboxylate compositions and method of making the same
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
JP7037069B2 (ja) * 2016-09-14 2022-03-16 ダイキン工業株式会社 分枝含フッ素化合物
RU2755181C2 (ru) 2016-11-28 2021-09-14 Байер Фарма Акциенгезельшафт Новые хелатные соединения гадолиния с высокой релаксивностью для применения в магнитно-резонансной визуализации
MX2021006024A (es) 2018-11-23 2021-07-06 Bayer Ag Formulacion de medios de contraste y proceso para prepararlos.
CN109867635A (zh) * 2019-02-14 2019-06-11 华东师范大学 一种t1型胶束磁共振成像造影剂及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19603033A1 (de) * 1996-01-19 1997-07-24 Schering Ag Perfluoralkylhaltige Metallkomplexe, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik
JPH10112939A (ja) * 1996-10-07 1998-04-28 Nec Corp 電源切替回路
DE19729013A1 (de) * 1997-07-03 1999-02-04 Schering Ag Oligomere, perfluoralkylhaltige Verbindungen, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik
US6019959A (en) * 1997-07-31 2000-02-01 Schering Aktiengesellschaft Oligomeric compounds that contain perfluoroalkyl, process for their production, and their use in NMR diagnosis

Also Published As

Publication number Publication date
HUP0300736A3 (en) 2010-01-28
CZ2003392A3 (cs) 2003-09-17
WO2002013874A2 (de) 2002-02-21
CA2419223A1 (en) 2003-02-11
YU10603A (sh) 2006-05-25
AU2001277549B2 (en) 2007-02-08
TWI296931B (en) 2008-05-21
CN1469757A (zh) 2004-01-21
HRP20030173A2 (en) 2005-04-30
BG107542A (bg) 2003-09-30
IL154385A0 (en) 2003-09-17
RU2290206C2 (ru) 2006-12-27
DE10066210B4 (de) 2008-02-28
NZ523932A (en) 2007-07-27
EE200300061A (et) 2004-12-15
AR034139A1 (es) 2004-02-04
AU7754901A (en) 2002-02-25
BR0113188A (pt) 2003-06-24
WO2002013874A8 (de) 2002-06-13
EP1307236A2 (de) 2003-05-07
ZA200301949B (en) 2004-12-14
SK1572003A3 (en) 2003-10-07
PL365596A1 (en) 2005-01-10
NO20030604L (no) 2003-04-11
KR20030022387A (ko) 2003-03-15
HUP0300736A2 (hu) 2003-09-29
UA82642C2 (uk) 2008-05-12
NO20030604D0 (no) 2003-02-07
JP2004506025A (ja) 2004-02-26

Similar Documents

Publication Publication Date Title
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
MXPA03001287A (es) Uso de complejos metalicos conteniendo perfluoroalquilo como medios de contraste en imagenes rm para la representacion de placas, tumores y necrosis.
PT1757606E (pt) Utilização de derivados de xantina como produto farmacêutico, bem como seu processo de preparação
IT1313599B1 (it) Complessi metallici utilizzabili nella catalisi per la (co)polimerizzazione delle alfa-olefine
PL367188A1 (en) Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents
EP1578347A4 (en) COMPOSITIONS AND METHODS FOR DETECTION, DIAGNOSIS AND THERAPY OF HEMATOLOGICAL MALIGNES DISEASES
AU2001277549A1 (en) Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses
IL154604A0 (en) Guanidinobenzamides as mc4-r agonists
AU2002352799A8 (en) Methods for evaluating drug-resistance gene expression in the cancer patient
HK1061212A1 (en) Pyranoindazoles and their use for the treatment ofglaucoma
MXPA03008739A (es) Anticuerpos recombinantes asociados a gangliosidos. su uso en el diagnostico y tratamiento de tumores.
ZA200205191B (en) LIV-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer.
HUP0400997A3 (en) Multidentate aza ligands able to complex metal ions and the use thereof in diagnostics and therapy
AU2002364607A1 (en) Novel ligand involved in the transmigration of leukocytes .
ITMC20000049A1 (it) Componente polivalente per cesti metallici scorrevoli, collocati all'interno di mobili.
ZA200307475B (en) Carbamate compounds for use in the treatment of pain.
ZA200400313B (en) Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine.
MXPA03002679A (es) Nuevo compuesto de oxabispidina util en el tratamiento de arritmias cardiacas.
AU2003281146A1 (en) Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of intravascular thrombes
SI1545710T1 (sl) Uporaba N-(3-metoksi-5-metilpirazin-2-il)-2-(4-(1,3,4-oksadiazol-2-il)fenil) piridin-3-sulfonamida v zdravljenju raka
HUP0400262A3 (en) Glycopeptides, their preparation and use in the treatment of multiple sclerosis
AU6022701A (en) Use of substituted acryloyl distamycin derivatives in the treatment of tumors associated with high levels of glutathione
IL160960A0 (en) Reduced toxicity cisplatin formulations and methods for using the same
HUP0100318A3 (en) Salicyli denaminoalcohol derivatives, their chiral copper complexes, their preparations and use of the latter
ZA200604529B (en) Platinum (II) complexes, preparation and use

Legal Events

Date Code Title Description
FG Grant or registration